This report provides a detailed analysis of the sustainability performance of 86 European companies in the Biotechnologies & Pharmaceuticals sector, based on EthiFinance’s ESG Ratings assessment conducted in 2024 with data reported for fiscal year 2023. The study highlights key trends and findings on the sector’s most material aspects across the four sustainability pillars—Environmental, Social, Governance, and External Stakeholders, offering insights into progress and challenges in sustainable practices.